Why Blood Work Matters in Peptide Research
Blood work is the cornerstone of responsible peptide research. It allows researchers to establish baseline values, monitor for intended and unintended changes, and detect potential adverse effects early. Whether studying metabolic peptides (e.g., GLP-1 agonists), growth hormone secretagogues, or tissue-repair peptides, blood testing provides objective data that subjective observation cannot.
This guide outlines the key biomarkers relevant to common peptide research categories, recommended testing intervals, and how to interpret results. All information is for research and educational purposes only.
Establishing a Baseline
Before beginning any peptide research protocol, obtain a comprehensive baseline blood panel. This serves three purposes:
- Identifies pre-existing conditions that may contraindicate certain peptides.
- Provides a reference point against which to measure changes.
- Establishes normal ranges for the individual, since laboratory reference ranges can vary.
A baseline panel should typically include:
- Full blood count (FBC)
- Comprehensive metabolic panel (CMP) — liver function, kidney function, electrolytes
- Fasting glucose and HbA1c
- Lipid profile (total cholesterol, LDL, HDL, triglycerides)
- Thyroid panel (TSH, free T3, free T4)
- Inflammatory markers (CRP, ESR)
Metabolic Peptides (GLP-1 Agonists, Dual/Triple Agonists)
Peptides such as semaglutide, tirzepatide, retatrutide, and liraglutide affect glucose metabolism, appetite regulation, and gastrointestinal function.
Key Markers
| Marker | Why It Matters | When to Test |
|---|---|---|
| Fasting glucose | Primary measure of glucose-lowering effect | Baseline, 4 weeks, 12 weeks |
| HbA1c | Long-term glycaemic control | Baseline, 12 weeks |
| Insulin / HOMA-IR | Insulin sensitivity changes | Baseline, 12 weeks |
| Lipid panel | GLP-1 agonists may improve cardiovascular risk markers | Baseline, 12 weeks |
| Pancreatic enzymes (lipase, amylase) | Monitor for pancreatic inflammation | Baseline, if symptoms arise |
| Kidney function (eGFR, creatinine) | Renal safety, especially with rapid weight loss | Baseline, 12 weeks |
| Liver enzymes (ALT, AST, GGT) | Monitor for MASH/fatty liver improvement or hepatic stress | Baseline, 12 weeks |
Interpreting Results
GLP-1 receptor agonists are expected to lower fasting glucose and HbA1c in diabetic or pre-diabetic subjects. Weight loss may improve liver enzymes and lipid profiles. Elevations in pancreatic enzymes (lipase, amylase) above the reference range warrant immediate investigation, as pancreatitis is a known adverse event associated with GLP-1 agonists.
Key reference: A 2024 population-based study in JAMA found an increased risk of pancreatitis with GLP-1 receptor agonists compared to other treatments (Refs et al., JAMA, 2024).
Growth Hormone Secretagogues (GHRPs, GHRHs)
Peptides such as ipamorelin, CJC-1295, sermorelin, GHRP-2, GHRP-6, and hexarelin stimulate growth hormone (GH) release, which in turn affects insulin-like growth factor 1 (IGF-1) and glucose metabolism.
Key Markers
| Marker | Why It Matters | When to Test |
|---|---|---|
| Serum IGF-1 | Primary biomarker for GH axis activity | Baseline, 4–6 weeks, 12 weeks |
| Fasting glucose and insulin | GH can reduce insulin sensitivity | Baseline, 6 weeks, 12 weeks |
| HbA1c | Longer-term glucose impact | Baseline, 12 weeks |
| Thyroid panel | GH can affect thyroid hormone conversion | Baseline, 12 weeks |
| Cortisol | GH and cortisol interact; monitor for dysregulation | Baseline, 12 weeks |
| Lipid panel | GH typically improves lipid profiles | Baseline, 12 weeks |
Interpreting Results
IGF-1 levels should rise with effective GH secretagogue use, but should remain within or near the age-adjusted reference range. Persistently elevated IGF-1 above the upper limit may indicate excessive dosing. Fasting glucose may rise slightly due to GH's anti-insulin effects; significant elevations warrant dose reduction or discontinuation.
Healing and Recovery Peptides (BPC-157, TB-500, Thymosin Beta-4)
These peptides are studied for tissue repair, anti-inflammatory effects, and recovery. Their mechanisms are less well-characterised in human trials, and blood monitoring focuses on safety.
Key Markers
| Marker | Why It Matters | When to Test |
|---|---|---|
| Inflammatory markers (CRP, ESR) | Track anti-inflammatory effects | Baseline, 4 weeks |
| Liver enzymes | Safety monitoring | Baseline, 6 weeks |
| Kidney function | Safety monitoring | Baseline, 6 weeks |
| Full blood count | Monitor for any haematological changes | Baseline, 6 weeks |
Interpreting Results
A reduction in CRP or ESR may indicate the intended anti-inflammatory effect. Any elevation in liver enzymes or changes in blood counts should be investigated. Given the limited human clinical data for many healing peptides, conservative monitoring intervals are recommended.
Cognitive and Neuroprotective Peptides (Semax, Selank, Dihexa, Cerebrolysin)
These peptides are studied for cognitive enhancement, neuroprotection, and anxiolysis. Blood monitoring is primarily for safety.
Key Markers
- Baseline metabolic panel — rule out contraindications
- Thyroid panel — some nootropic peptides may affect endocrine function
- Cortisol — monitor for HPA axis effects
- Liver and kidney function — safety monitoring at 6–12 weeks
Testing Frequency: General Framework
| Phase | Timing | Purpose |
|---|---|---|
| Baseline | Before starting | Establish reference values, screen for contraindications |
| Early monitoring | 4–6 weeks | Detect acute changes, assess tolerance |
| Mid-cycle | 12 weeks | Evaluate cumulative effects |
| Post-cycle | 2–4 weeks after discontinuation | Assess recovery to baseline |
Practical Considerations
UK Testing Access
In the UK, blood tests can be obtained through:
- NHS — Via a GP when clinically indicated. Research-only requests may not be accommodated.
- Private blood testing services — Companies such as Medichecks, Thriva, and Nuffield Health offer self-requested blood panels. These provide a practical route for researchers who need specific markers.
- Private clinics — Some private clinics offer comprehensive panels with interpretation.
Working with Reference Ranges
Laboratory reference ranges vary. Always compare results to the specific laboratory's stated range, not to values from other sources. Track trends over time rather than focusing on a single value — a result within the reference range that has shifted significantly from baseline may still be meaningful.
Red Flags
Seek immediate medical attention if blood work shows:
- Elevated pancreatic enzymes (lipase, amylase) above reference range
- Significant elevation in liver enzymes (ALT/AST >3× upper limit)
- Decline in kidney function (rising creatinine, falling eGFR)
- Significant changes in blood count (anaemia, leukopenia, thrombocytopenia)
- Severe hyperglycaemia or hypoglycaemia
Important Disclaimer
This guide is for research and educational purposes only. It does not constitute medical advice. Peptides discussed are not licensed medicines and are not approved for human consumption unless stated otherwise. Blood work interpretation should be conducted by a qualified healthcare professional. Always consult a medical professional before beginning or modifying any research protocol.